Search

Your search keyword '"Jusko WJ"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Jusko WJ" Remove constraint Author: "Jusko WJ" Publisher springer Remove constraint Publisher: springer
50 results on '"Jusko WJ"'

Search Results

1. Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.

2. Pathway-level analysis of genome-wide circadian dynamics in diverse tissues in rat and mouse.

3. Mathematical modeling of mammalian circadian clocks affecting drug and disease responses.

4. Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women.

5. Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women.

7. Indirect pharmacodynamic models for responses with circadian removal.

8. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.

9. Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver.

10. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.

11. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.

12. Assessment of non-linear combination effect terms for drug-drug interactions.

13. Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis.

14. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.

15. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.

18. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.

19. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

20. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach.

21. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

22. Applications of minimal physiologically-based pharmacokinetic models.

23. Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test.

24. Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.

25. Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats.

26. Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats.

27. D-optimal designs for parameter estimation for indirect pharmacodynamic response models.

28. Methods of utilizing baseline values for indirect response models.

29. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

30. Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids.

31. Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling.

32. Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models.

33. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.

34. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

35. Assessment of basic indirect pharmacodynamic response models with physiological limits.

36. Population cell life span models for effects of drugs following indirect mechanisms of action.

37. Assessment of drug interactions relevant to pharmacodynamic indirect response models.

38. Gene arrays and temporal patterns of drug response: corticosteroid effects on rat liver.

39. Multiple-pool cell lifespan model of hematologic effects of anticancer agents.

40. Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis.

41. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats.

42. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

43. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.

44. Pharmacodynamic modeling of cortisol suppression from fluocortolone.

45. Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers.

46. Disposition of pulse dose methylprednisolone in adult and paediatric patients with the nephrotic syndrome.

47. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline.

48. Effect of chronic oral contraceptive steroids on theophylline disposition.

49. Pharmacokinetic approach to intravenous procainamide therapy.

50. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.

Catalog

Books, media, physical & digital resources